Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Pete who wrote (449)	2/28/1999 11:58:00 AM
From: checkmate	Respond to of 792

Without any doubt this is the intent. But some isomers may have advantages over the parent compound. Just adding a few carbons, a F, a cl or other elements can also alter the medications profile. This is what sepr is doing. You know what--they will succeed. This is not really new stuff..."ethical" pharm cos have been doing this for a long time. They will take an effective compound and play around with it until they can come up with a form they can patent and market. As for their profile..nothinh is written in stone. If they feel they can play around with Vancomycin..Methacillin etc and get a new hit on VRS they will. Just my thoughts.